How many drugs treat Vasomotor rhinitis?

Drug Landscape tracks 10 marketed treatments for Vasomotor rhinitis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/vasomotor-rhinitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Vasomotor rhinitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vasomotor rhinitis (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Vasomotor rhinitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Clarinex	desloratadine	Generic (originally Schering-Plough/MSD)	Histamine-1 Receptor Antagonist [EPC]	5-hydroxytryptamine receptor 6, Histamine H4 receptor, Multidrug resistance protein 1	2001-12-21
Propadrine	PHENYLPROPANOLAMINE	Alpharma Us Pharms	Indirectly Acting Sympathomimetic Amines	Sodium-dependent noradrenaline transporter	2000-01-01
Astelin	AZELASTINE	Bayer	Histamine-1 Receptor Antagonist	Histamine H1 receptor	1996-01-01
Zyrtec	cetirizine	Generic (originally UCB Pharma)	Second-generation antihistamine	Angiopoietin-1 receptor, Histamine H1 receptor, Potassium voltage-gated channel subfamily H member 2	1995-09-29
Semprex-D	ACRIVASTINE	Auxilium Pharms Inc	Histamine-1 Receptor Antagonist	Histamine H1 receptor	1994-01-01
Claritin	loratadine	Generic (originally Schering-Plough)	Second-generation antihistamine	Sodium-dependent neutral amino acid transporter B(0)AT2, Cytochrome P450 2C19, Multidrug resistance protein 1	1993-04-12
Phenazoline	ANTAZOLINE	Novartis	antazoline	Histamine H1 receptor	1990-01-01
Actidil	TRIPROLIDINE	Novartis	triprolidine	Histamine H1 receptor	1983-01-01
Hispril	DIPHENYLPYRALINE	GSK	diphenylpyraline	Histamine H1 receptor	1982-01-01
Marezine	CYCLIZINE	GSK	cyclizine	Histamine H1 receptor	1982-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 14 drugs in Vasomotor rhinitis
Novartis · 3 drugs in Vasomotor rhinitis
Bayer · 3 drugs in Vasomotor rhinitis
Generic (multiple manufacturers) · 2 drugs in Vasomotor rhinitis
GSK · 2 drugs in Vasomotor rhinitis
Chattem · 1 drug in Vasomotor rhinitis
Brooke Army Medical Center · 1 drug in Vasomotor rhinitis
Alpharma Us Pharms · 1 drug in Vasomotor rhinitis
Generic (originally Roche) · 1 drug in Vasomotor rhinitis
Fougera Pharms · 1 drug in Vasomotor rhinitis
Generic (originally Schering-Plough) · 1 drug in Vasomotor rhinitis
Auxilium Pharms Inc · 1 drug in Vasomotor rhinitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Vasomotor rhinitis:

Cite this brief

Drug Landscape (2026). Vasomotor rhinitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/vasomotor-rhinitis. Accessed 2026-06-10.

Vasomotor rhinitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing